Home | Neurology Live

Clinical Focus

Video Series

Publications

Current Issue

Genetic Targets Invigorate Research for Duchenne Muscular Dystrophy

COMT Inhibitors Assist in Control of Parkinson Disease Motor Symptoms

Reldesemtiv Displays Promise Over Predecessor for ALS, Currently in Phase 2b Trial

Advances Answer Some Questions in Excessive Sleepiness, But Raise New Ones

Neuromodulation and Stimulation Devices Offer Additional Options to Patients With Headache Disorders

Drawing on Blood for Biomarkers of Alzheimer Disease

Insight from Daniel Barber, MBA

FDA Accepts NDA for Riluzole Oral Film for ALS

The Aquestive Therapeutics product, marketed as Exservan, was previously granted an orphan drug designation in January 2018. Its NDA is supported by a number of studies which sought to confirm its bioequivalence to its reference listed drug.

Pascal Sati, PhD: Challenges in Imaging for Multiple Sclerosis

The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke gave a presentation on a volumetric segmented echo-planar-imaging (3D-EPI) sequence, which could be used to detect novel biomarkers such as the central vein sign rapidly.

Erenumab Efficacious In Episodic Migraine Patients With Prior Treatment Failure

The study also added to a growing base of findings which suggest that patients who have failed preventive medications prior to trial participation have lower placebo responses, which could have implications for clinical trial design.

Duchenne Muscular Dystrophy Treatment Pamrevlumab Receives Orphan Drug Designation

In an ongoing phase 2 study, 21 nonambulatory participants with Duchenne muscular dystrophy passed the 52-week treatment mark.

Migraine Days Reduced Long-Term After Galcanezumab Treatment Cessation

Data from the EVOLVE-1 and EVOLVE-2 phase 3 clinical trials suggest that galcanezumab (Emgality, Eli Lilly) can maintain ≥50% responder rates equivalent to that of placebo while reducing more monthly migraine days for 5 months after halting treatment.

Epilepsy and the Evolving Treatment Choices

Compliance and the Prevention of Breakthrough Seizures

Managing Epilepsy: Parting Advice for Neurologists